Drug Targeting and Stimuli Sensitive Drug Delivery Systems covers recent advances in the area of stimuli sensitive drug delivery systems, providing an up-to-date overview of the physical, chemical, biological and multistimuli-responsive nanosystems. In addition, the book presents an analysis of clinical status for different types of nanoplatforms. Written by an internationally diverse group of researchers, it is an important reference resource for both biomaterials scientists and those working in the pharmaceutical industry who are looking to help create more effective drug delivery systems. - Shows how the use of nanomaterials can help target a drug to specific tissues and cells - Explores the development of stimuli-responsive drug delivery systems - Includes case studies to showcase how stimuli responsive nanosystems are used in a variety of therapies, including camptothecin delivery, diabetes and cancer therapy

This authoritative volume explores the fundamental concepts and numerous applications of targeted delivery of drugs to the body. This compilation has been divided into eight sections comprised of the basic principles of drug targeting, disease and organ/organelle-based targeting, passive and active targeting strategies, and various advanced drug delivery tools such as functionalized lipidic, polymeric and inorganic nanocarriers. Together, the twenty-three chapters cover a wide range of topics in the field, including tumor and hepatic targeting, polymer-drug conjugates, nanoemulsion, physical and biophysical characteristics of nanoparticles, and in vivo imaging techniques, among others. The book also examines advanced characterization techniques, regulatory hurdles and toxicity-related issues that are key features for successful commercialization of targeted drug delivery system products. Targeted Drug Delivery is a comprehensive reference guide for drug delivery researchers, both beginners and those already working in the field.

Nano-carriers for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery presents recent discoveries in research on the pharmaceutical applications of the various types of nanosystem-based drug delivery systems. As many nanosystems have reached the market over the past decade, this book proves their benefits to patients. It explores these new carriers and the advances in drug delivery they have facilitated. Reflecting the interdisciplinary nature of the subject matter, the book includes experts from different fields, and with various backgrounds and expertise. It will appeal to researchers and students from different disciplines, such as materials science, technology and various biomedical fields. Coverage includes industrial applications that bridge the gap between lab-based research and practical industrial use. The resulting work is a reference and practical source of guidance for researchers, students and scientists working in the fields of nanotechnology, materials science and technology and biomedical science.

Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes provides an overview of the important aspects of nanomedicine in order to illustrate how to design and develop novel and effective drug delivery systems using nanotechnology. The book is organized into three sections, beginning with an introduction to nanomedicine and its associated issues. Section two discusses the latest technologies in nanomedicine, while the third section covers future developments and challenges in the field. By focusing on the design, synthesis, and application of a variety of nanocarriers in drug and gene delivery, this book provides pharmaceutical and materials science students, professors, clinical researchers, and industry scientists with a valuable resource aimed at tackling the challenges of delivering drugs and genes in a more targeted manner. - Explores a wide range of promising approaches for the diagnosis and treatment of diseases using the latest advances in cutting-edge nanomedical technologies - Contains contributions from world-renowned experts and researchers working in the area of nanomedicine and drug delivery - Covers the associated challenges and potential solutions to working with nanotechnology in drug delivery - Highlights crucial topics, such as biopharmaceutical and toxicity issues, quality by design, drug targeting, and more

This unique book is the only one to discuss various new techniques developed to enhance the application of nanoparticulate drug delivery systems using surface modification of nanoparticles. The understanding of the surface characteristics nano-particles is growing significantly with the advent of new analytical techniques. Polymer chemistry is contributing to the development of many new versatile polymers which have abilities to accommodate many different, very reactive chemical groups, and can be used as a diagnostic tool, for better targeting, for more effective therapeutic results as well as for reducing the toxic and side effects of the drugs. Surface modification of such polymeric nanoparticles has been found by many scientists to enhance the application of nanoparticles and also allows the nano particles to carry specific drug molecule and disease /tumor specific antibodies which refine and improve drug delivery. Surface Modification of Nanoparticles for Targeted Drug Delivery is a collection essential information with various applications of surface modification of nanoparticles and their disease specific applications for therapeutic purposes.

Modeling and Control of Drug Delivery Systems provides comprehensive coverage of various drug delivery and targeting systems and their state-of-the-art related works, ranging from theory to real-world deployment and future perspectives. Various drug delivery and targeting systems have been developed to minimize drug degradation and adverse effect and increase drug bioavailability. Site-specific drug delivery may be either an active and/or passive process. Improving delivery techniques that minimize toxicity and increase efficacy offer significant potential benefits to patients and open up new markets for pharmaceutical companies. This book will attract many researchers working in DDS field as it provides an essential source of information for pharmaceutical scientists and pharmacologists working in academia as well as in the industry. In addition, it has useful information for pharmaceutical physicians and scientists in many disciplines involved in developing DDS, such as chemical engineering, biomedical engineering, protein engineering, gene therapy. - Presents some of the latest innovations of approaches to DDS from dynamic controlled drug delivery, modeling, system analysis, optimization, control and monitoring - Provides a unique, recent and comprehensive reference on DDS with the focus on cutting-edge technologies and the latest research trends in the area - Covers the most recent works, in particular, the challenging areas related to modeling and control techniques applied to DDS

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

This book describes the authors’ standard or ‘best’ practices used in writing regul- ed clinical documents for the drug and biologics industry. The fundamental premise of this book is that the end (documents submitted to a health authority) is dep- dent on the beginning (the planning and strategy that go into organizing written documentation). Each regulatory document inherently exists within a constellation of related documents. This book attempts to show the relationships between and among these documents and suggests strategies for organizing and writing these documents to maximize ef?ciency while developing clear and concise text. At all times, and irrespective of applicable laws and guidelines, good communication skills and a sense of balance are essential to adequately, accurately, and clearly describe a product’s characteristics. At no time should the reader perceive these suggestions to be the only viable solution to writing regulatory documents nor should the reader expect that these suggestions guarantee product success. The audience for this book is the novice medical writer, or those who would like to explore or enhance regulatory-writing skills. We assume the reader will have a basic understanding of written communication, but little experience in applying this skill to the task of regulatory writing. Extensive knowledge of science, clinical me- cine, mathematics, or regulatory affairs law is not required to use the best practices described in this book.

Respiratory diseases affect millions of people each year and represent a major health burden around the world. This timely reference surveys and evaluates the drug treatments available for the main categories of lung diseases including asthma, tuberculosis, chronic obstructive pulmonary disease, lung cancer, and respiratory infections. The recent re-emergence of tuberculosis and the increase in asthma in certain populations underlines the importance of finding effective new treatments for these diseases. This publication, a comprehensive reference, is one of the first to survey current and novel drug treatments for this group of diseases. It is certain to establish itself as an essential source of reference for respiratory physicians, clinicians and clinical pharmacologists.